Mesa Laboratories (MLAB) Q2 2025 earnings summary

Executive summary

• Revenues for the six months ended September 30, 2024 increased 11.7% year-over-year to $116.0 million, driven by the GKE acquisition and strong Biopharmaceutical Development growth.

• Net income for the six months was $6.8 million, compared to a net loss of $1.8 million in the prior year period; 2Q25 net income increased 379% to $3,428.

• Operating income rose to $9.1 million from a loss of $0.7 million year-over-year, with 2Q25 operating income up 5,947% to $3,508.

• GKE contributed $12.1 million in revenues and $4.5 million in operating income in the first half of fiscal 2025; acquisition completed December 2023.

• Sequential order growth and reductions in inventory and debt were achieved, with net leverage ratio reduced to 3.26.

Financial highlights

• Gross profit margin increased to 62.7% for the six months ended September 30, 2024, up 1.7 percentage points year-over-year; 2Q25 gross profit was $35,455.

• Operating expenses declined 0.6% year-over-year despite higher revenues, aided by lower amortization from prior asset impairments.

• Cash and cash equivalents were $24.3 million as of September 30, 2024.

• Adjusted operating income (AOI) excluding unusual items grew 18.9% to $14,352, representing 24.8% of revenues.

• Cash flow from operations was $15.7 million for the six months, down from $19.7 million due to higher interest and tax payments.

Outlook and guidance

• Management expects positive organic revenue growth in the Sterilization and Disinfection Control division for fiscal 2025 as backlog is fulfilled.

• Anticipates strong year-over-year growth in BPD and continued sequential growth in CG, CS, and SDC for 3Q25.

• GKE's gross margin is expected to be in the low 70s beginning in Q3 fiscal 2025 as purchase accounting charges subside.

• Sufficient liquidity is anticipated to meet debt obligations and operating needs over the next 12 months.

• Remains focused on driving net leverage ratio below 3.0x and investing in long-term growth initiatives.